Gauri Godbole
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Gauri Godbole has a total of 274 co-authors. Here are the top co-authors by number of shared publications:
- Claire Jenkins
Gastrointestinal Bacteria Reference Unit, UK Health Security Agency , London NW9 5HT
8 shared publications - Marie Anne Chattaway
Gastrointestinal Bacteria Reference Unit, United Kingdom Health Security Agency, London, United Kingdom
5 shared publications - Satheesh Nair
Gastrointestinal Bacteria Reference Unit, UK Health Security Agency, London NW9 5HT, UK
5 shared publications - Aileen Mill
Newcastle University, Newcastle upon Tyne, United Kingdom
3 shared publications Claire Jenkins
Gastrointestinal Pathogens Department, National Infection Service, Public Health England, London, UK
3 shared publications- Daniel Hungerford
University of Liverpool
3 shared publications
Latest Publications
- Open Access
- 25 February 2026
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 15, e88759
The Third Study of Infectious Intestinal Disease (IID3 Study) in the Community: Protocol for UK-Based Prospective Cohort Studies Investigating the Disease Burden
Background: There is a significant hidden burden of infectious intestinal disease (IID) in the UK community, which has increased over time. In the late 2000s, the Second Study of Infectious Intestinal Disease (IID2 study) estimated 17 million IID cases annually in the United Kingdom. However, only a small proportion of cases present to health care, and even those are often not tested for causative organisms. Objective: The Third Study of Infectious Intestinal Disease (IID3 study) aims to determine the IID burden in the UK community, estimate the underreporting level in routine practice and the general population, and recalibrate UK national surveillance based on the new incidence rates. Methods: We will follow methods of previous studies, along with modern pathogen detection methods and digital platforms for recruitment and follow-up. Participants will be recruited to three population-based prospective cohorts: cohort 1 (the general population), cohort 2 (patients with IID presenting to general practices [GPs]), and cohort 3 (enumeration study of IID cases presenting to GPs). Microbiological analysis of stool samples in cohorts 1 and 2 will include testing for a wide range of causative organisms using molecular assays, including pathogen targets not routinely sought by National Health Service (NHS) laboratories. Additional characterization of pathogens will be conducted at national reference laboratories. The incidence rates of IID and organisms detected in cohorts 1-3 will be compared to national surveillance systems, both laboratory and syndromic. Descriptive statistics and analysis will allow comparison of IID rates within each cohort, estimate the overall burden of disease caused by different pathogens, and compare findings to earlier IID studies. Results: A favorable ethical opinion was obtained from the UK Health Research Authority on August 4, 2022. A pilot phase to test the sampling process was conducted from January to August 2023. Participant recruitment commenced on September 1, 2023, for cohort 2 and on March 16, 2024, for cohort 1; recruitment ceased on August 31, 2025. Data collection is complete, and data analysis is to begin. The study is expected to end in September 2026. Conclusions: Since the first and second IID studies, changes have occurred within national surveillance systems, the NHS structure, and public recommendations about when to consult a GP and where to seek health care advice, which may have altered the extent of IID reporting and the perceived burden in the community, creating greater uncertainty about the representativeness of IID rates. The IID3 study results will provide insight into trends in disease incidence over time and help quantify inequalities in IID in the UK community. Revised estimates can inform policy related to prevention, including food standards and disease management. Furthermore, advances in molecular diagnostics will significantly enhance pathogen detection, increasing our understanding of the causes of IID. International Registered Report Identifier (IRRID): DERR1-10.2196/88759
- 25 February 2026
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 15, e88759
Open AccessThe Third Study of Infectious Intestinal Disease (IID3 Study) in the Community: Protocol for UK-Based Prospective Cohort Studies Investigating the Disease Burden
Background: There is a significant hidden burden of infectious intestinal disease (IID) in the UK community, which has increased over time. In the late 2000s, the Second Study of Infectious Intestinal Disease (IID2 study) estimated 17 million IID cases annually in the United Kingdom. However, only a small proportion of cases present to health care, and even those are often not tested for causative organisms. Objective: The Third Study of Infectious Intestinal Disease (IID3 study) aims to determine the IID burden in the UK community, estimate the underreporting level in routine practice and the general population, and recalibrate UK national surveillance based on the new incidence rates. Methods: We will follow methods of previous studies, along with modern pathogen detection methods and digital platforms for recruitment and follow-up. Participants will be recruited to three population-based prospective cohorts: cohort 1 (the general population), cohort 2 (patients with IID presenting to general practices [GPs]), and cohort 3 (enumeration study of IID cases presenting to GPs). Microbiological analysis of stool samples in cohorts 1 and 2 will include testing for a wide range of causative organisms using molecular assays, including pathogen targets not routinely sought by National Health Service (NHS) laboratories. Additional characterization of pathogens will be conducted at national reference laboratories. The incidence rates of IID and organisms detected in cohorts 1-3 will be compared to national surveillance systems, both laboratory and syndromic. Descriptive statistics and analysis will allow comparison of IID rates within each cohort, estimate the overall burden of disease caused by different pathogens, and compare findings to earlier IID studies. Results: A favorable ethical opinion was obtained from the UK Health Research Authority on August 4, 2022. A pilot phase to test the sampling process was conducted from January to August 2023. Participant recruitment commenced on September 1, 2023, for cohort 2 and on March 16, 2024, for cohort 1; recruitment ceased on August 31, 2025. Data collection is complete, and data analysis is to begin. The study is expected to end in September 2026. Conclusions: Since the first and second IID studies, changes have occurred within national surveillance systems, the NHS structure, and public recommendations about when to consult a GP and where to seek health care advice, which may have altered the extent of IID reporting and the perceived burden in the community, creating greater uncertainty about the representativeness of IID rates. The IID3 study results will provide insight into trends in disease incidence over time and help quantify inequalities in IID in the UK community. Revised estimates can inform policy related to prevention, including food standards and disease management. Furthermore, advances in molecular diagnostics will significantly enhance pathogen detection, increasing our understanding of the causes of IID. International Registered Report Identifier (IRRID): DERR1-10.2196/88759
- Open Access
Case Fatality Risk of Norovirus in England During a Period of Strain Replacement, 2022/23 - 2024/25 Seasons
Background Norovirus causes substantial burden to healthcare systems. England experienced high activity in recent seasons alongside a shift in the dominant genotype from GII.4 to GII.17. It remains unclear whether this increased burden reflects changes in severity or other transmission mechanisms associated with the strain replacement. Methods Individual-level testing and mortality data in England from 2022/23-2024/25 seasons were linked from national surveillance systems. Piece-wise exponential additive mixed models estimated all-cause case-fatality risk (CFR) for death within 28 days of a positive test, adjusting for age, location, primary or secondary care case identification and temporal effects. Additional analysis tested the effect of the death linkage threshold. Results CFR did not differ significantly between GII.4 and GII.17, but increased markedly with age and was substantially higher for cases detected in secondary versus primary care. At the 2024/25 season peak, the CFR for the average cohort case (age 75) was 8.01% (95% CI: 6.88-9.33%) for cases identified in secondary care compared with 1.18% (95% CI: 0.61-2.25%) for primary care, likely driven by different case mixes and unmeasured confounding between patients managed in these settings. Interpretation We found no evidence that the newly dominant GII.17 genotype had higher CFR than GII.4 among test-positive cases. The increased burden is therefore more consistent with changes in transmissibility, population immunity, or testing dynamics than increased genotype-specific severity. Norovirus remains a major public health threat, and understanding genotype switching supports enhanced surveillance, expanded genotyping, routine clinical data linkage and advanced modelling to inform control strategies.
Open AccessCase Fatality Risk of Norovirus in England During a Period of Strain Replacement, 2022/23 - 2024/25 Seasons
Background Norovirus causes substantial burden to healthcare systems. England experienced high activity in recent seasons alongside a shift in the dominant genotype from GII.4 to GII.17. It remains unclear whether this increased burden reflects changes in severity or other transmission mechanisms associated with the strain replacement. Methods Individual-level testing and mortality data in England from 2022/23-2024/25 seasons were linked from national surveillance systems. Piece-wise exponential additive mixed models estimated all-cause case-fatality risk (CFR) for death within 28 days of a positive test, adjusting for age, location, primary or secondary care case identification and temporal effects. Additional analysis tested the effect of the death linkage threshold. Results CFR did not differ significantly between GII.4 and GII.17, but increased markedly with age and was substantially higher for cases detected in secondary versus primary care. At the 2024/25 season peak, the CFR for the average cohort case (age 75) was 8.01% (95% CI: 6.88-9.33%) for cases identified in secondary care compared with 1.18% (95% CI: 0.61-2.25%) for primary care, likely driven by different case mixes and unmeasured confounding between patients managed in these settings. Interpretation We found no evidence that the newly dominant GII.17 genotype had higher CFR than GII.4 among test-positive cases. The increased burden is therefore more consistent with changes in transmissibility, population immunity, or testing dynamics than increased genotype-specific severity. Norovirus remains a major public health threat, and understanding genotype switching supports enhanced surveillance, expanded genotyping, routine clinical data linkage and advanced modelling to inform control strategies.
- Open Access
- 1 December 2025
- Published by JMIR Publications Inc. in JMIR Preprints
The Third Study of Infectious Intestinal Disease (IID3 Study) in the Community: Protocol for UK-Based Prospective Cohort Studies Investigating the Disease Burden (Preprint)
BACKGROUND There is a significant hidden burden of infectious intestinal disease (IID) in the UK community, which has increased over time. In the late 2000s, the Second Study of Infectious Intestinal Disease (IID2 study) estimated 17 million IID cases annually in the United Kingdom. However, only a small proportion of cases present to health care, and even those are often not tested for causative organisms. OBJECTIVE The Third Study of Infectious Intestinal Disease (IID3 study) aims to determine the IID burden in the UK community, estimate the underreporting level in routine practice and the general population, and recalibrate UK national surveillance based on the new incidence rates. METHODS We will follow methods of previous studies, along with modern pathogen detection methods and digital platforms for recruitment and follow-up. Participants will be recruited to three population-based prospective cohorts: cohort 1 (the general population), cohort 2 (patients with IID presenting to general practices [GPs]), and cohort 3 (enumeration study of IID cases presenting to GPs). Microbiological analysis of stool samples in cohorts 1 and 2 will include testing for a wide range of causative organisms using molecular assays, including pathogen targets not routinely sought by National Health Service (NHS) laboratories. Additional characterization of pathogens will be conducted at national reference laboratories. The incidence rates of IID and organisms detected in cohorts 1-3 will be compared to national surveillance systems, both laboratory and syndromic. Descriptive statistics and analysis will allow comparison of IID rates within each cohort, estimate the overall burden of disease caused by different pathogens, and compare findings to earlier IID studies. RESULTS A favorable ethical opinion was obtained from the UK Health Research Authority on August 4, 2022. A pilot phase to test the sampling process was conducted from January to August 2023. Participant recruitment commenced on September 1, 2023, for cohort 2 and on March 16, 2024, for cohort 1; recruitment ceased on August 31, 2025. Data collection is complete, and data analysis is to begin. The study is expected to end in September 2026. CONCLUSIONS Since the first and second IID studies, changes have occurred within national surveillance systems, the NHS structure, and public recommendations about when to consult a GP and where to seek health care advice, which may have altered the extent of IID reporting and the perceived burden in the community, creating greater uncertainty about the representativeness of IID rates. The IID3 study results will provide insight into trends in disease incidence over time and help quantify inequalities in IID in the UK community. Revised estimates can inform policy related to prevention, including food standards and disease management. Furthermore, advances in molecular diagnostics will significantly enhance pathogen detection, increasing our understanding of the causes of IID. INTERNATIONAL REGISTERED REPORT DERR1-10.2196/88759
- 1 December 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessThe Third Study of Infectious Intestinal Disease (IID3 Study) in the Community: Protocol for UK-Based Prospective Cohort Studies Investigating the Disease Burden (Preprint)
BACKGROUND There is a significant hidden burden of infectious intestinal disease (IID) in the UK community, which has increased over time. In the late 2000s, the Second Study of Infectious Intestinal Disease (IID2 study) estimated 17 million IID cases annually in the United Kingdom. However, only a small proportion of cases present to health care, and even those are often not tested for causative organisms. OBJECTIVE The Third Study of Infectious Intestinal Disease (IID3 study) aims to determine the IID burden in the UK community, estimate the underreporting level in routine practice and the general population, and recalibrate UK national surveillance based on the new incidence rates. METHODS We will follow methods of previous studies, along with modern pathogen detection methods and digital platforms for recruitment and follow-up. Participants will be recruited to three population-based prospective cohorts: cohort 1 (the general population), cohort 2 (patients with IID presenting to general practices [GPs]), and cohort 3 (enumeration study of IID cases presenting to GPs). Microbiological analysis of stool samples in cohorts 1 and 2 will include testing for a wide range of causative organisms using molecular assays, including pathogen targets not routinely sought by National Health Service (NHS) laboratories. Additional characterization of pathogens will be conducted at national reference laboratories. The incidence rates of IID and organisms detected in cohorts 1-3 will be compared to national surveillance systems, both laboratory and syndromic. Descriptive statistics and analysis will allow comparison of IID rates within each cohort, estimate the overall burden of disease caused by different pathogens, and compare findings to earlier IID studies. RESULTS A favorable ethical opinion was obtained from the UK Health Research Authority on August 4, 2022. A pilot phase to test the sampling process was conducted from January to August 2023. Participant recruitment commenced on September 1, 2023, for cohort 2 and on March 16, 2024, for cohort 1; recruitment ceased on August 31, 2025. Data collection is complete, and data analysis is to begin. The study is expected to end in September 2026. CONCLUSIONS Since the first and second IID studies, changes have occurred within national surveillance systems, the NHS structure, and public recommendations about when to consult a GP and where to seek health care advice, which may have altered the extent of IID reporting and the perceived burden in the community, creating greater uncertainty about the representativeness of IID rates. The IID3 study results will provide insight into trends in disease incidence over time and help quantify inequalities in IID in the UK community. Revised estimates can inform policy related to prevention, including food standards and disease management. Furthermore, advances in molecular diagnostics will significantly enhance pathogen detection, increasing our understanding of the causes of IID. INTERNATIONAL REGISTERED REPORT DERR1-10.2196/88759
- Open Access
The third study of infectious intestinal disease in the community microbiological methods
Introduction: Infectious intestinal disease (IID) is a significant public health concern, with an estimated 17 million cases occurring annually in the UK. However, only a small proportion of cases in the community present to primary health care, and those that do may not be tested for the causative pathogen. The third study of IID in the community (IID3 study) will provide updated estimates of the incidence and aetiology of IID in the UK. This protocol describes the laboratory methods employed by the IID3 study in primary diagnostic and reference laboratories. Methods and analysis: Stool specimens obtained from symptomatic subjects enrolled in two cohorts recruited prospectively through Primary Care in the UK are tested for 21 pathogens using PCR-based methods, in two separate workflows at Liverpool Clinical Laboratories. The first workflow comprises EntericBio DX, Viral and Clostridium difficile assays (Serosep, Crawley, UK); and the second a panel of assays for detection of Clostridium perfringens, Aeromonas spp., Cyclospora cayetanensis and diarrhoeagenic Escherichia coli based on 3base® Technology (Genetic Signatures, Newtown, Australia). Specimens testing positive for bacterial pathogens are subjected to culture. Specimens positive for, and isolates of Salmonella, Campylobacter, Yersinia, Vibrio and Shigella species and diarrhoeagenic E. coli are referred to the Gastrointestinal Bacteria Reference Unit, UK Health Security Agency (UKHSA) for whole genome sequencing and antimicrobial susceptibility testing. The parasites Cryptosporidium , Giardia and Cyclospora are referred for genotyping to the national Cryptosporidium Reference Unit, Public Health Wales. Norovirus positive faecal specimens are referred for Sanger Sequencing-based genotyping to the Enteric Virus Unit, UKHSA. Ethics and dissemination: Favourable ethical opinion was granted on the 10 th of August 2022 by the East Midlands - Nottingham 1 Research Ethics Committee (IRAS ID 314268, REC Reference 22/EM/0130). The results will be disseminated to key stakeholders including the Food Standards Agency, participating general practices and to the academic community through publications and conference presentations. A real-time breakdown of pathogens identified in faecal samples could be viewed openly on the study Dashboard throughout the surveillance period. Article Summary: Strengths and limitations of this study: - A total of 5439 stool samples underwent molecular testing for a total of 21 organisms at the Liverpool Clinical Laboratories (LCL), with detailed pathogen characterisation at national reference laboratories. - A commercial Genetic Signatures assay was evaluated in a routine diagnostic setting using commercially-provided pathogen controls, reference isolates and clinical samples, enabling the inclusion of Aeromonas and ETEC PCR targets into the diagnostic panel. - Real-time referrals of PCR-reactive samples were made to UK Health Security Agency (UKHSA) regardless of bacterial culture results, and to Public Health Wales (PHW). - Norovirus PCR-reactive samples were referred to the Enteric Virus Unit at UKHSA for genotyping ahead of Norovirus becoming a notifiable infection on the 6 th of April 2025, adding valuable information on Norovirus genotypes circulating in the general population. - A Biobank has been created for residual faecal specimens, forming a rich resource for future studies. - A major challenge was the lack of a harmonised UK-wide digital referral and reporting system, resulting in an inflated manual reporting workload for staff at LCL.
Open AccessThe third study of infectious intestinal disease in the community microbiological methods
Introduction: Infectious intestinal disease (IID) is a significant public health concern, with an estimated 17 million cases occurring annually in the UK. However, only a small proportion of cases in the community present to primary health care, and those that do may not be tested for the causative pathogen. The third study of IID in the community (IID3 study) will provide updated estimates of the incidence and aetiology of IID in the UK. This protocol describes the laboratory methods employed by the IID3 study in primary diagnostic and reference laboratories. Methods and analysis: Stool specimens obtained from symptomatic subjects enrolled in two cohorts recruited prospectively through Primary Care in the UK are tested for 21 pathogens using PCR-based methods, in two separate workflows at Liverpool Clinical Laboratories. The first workflow comprises EntericBio DX, Viral and Clostridium difficile assays (Serosep, Crawley, UK); and the second a panel of assays for detection of Clostridium perfringens, Aeromonas spp., Cyclospora cayetanensis and diarrhoeagenic Escherichia coli based on 3base® Technology (Genetic Signatures, Newtown, Australia). Specimens testing positive for bacterial pathogens are subjected to culture. Specimens positive for, and isolates of Salmonella, Campylobacter, Yersinia, Vibrio and Shigella species and diarrhoeagenic E. coli are referred to the Gastrointestinal Bacteria Reference Unit, UK Health Security Agency (UKHSA) for whole genome sequencing and antimicrobial susceptibility testing. The parasites Cryptosporidium , Giardia and Cyclospora are referred for genotyping to the national Cryptosporidium Reference Unit, Public Health Wales. Norovirus positive faecal specimens are referred for Sanger Sequencing-based genotyping to the Enteric Virus Unit, UKHSA. Ethics and dissemination: Favourable ethical opinion was granted on the 10 th of August 2022 by the East Midlands - Nottingham 1 Research Ethics Committee (IRAS ID 314268, REC Reference 22/EM/0130). The results will be disseminated to key stakeholders including the Food Standards Agency, participating general practices and to the academic community through publications and conference presentations. A real-time breakdown of pathogens identified in faecal samples could be viewed openly on the study Dashboard throughout the surveillance period. Article Summary: Strengths and limitations of this study: - A total of 5439 stool samples underwent molecular testing for a total of 21 organisms at the Liverpool Clinical Laboratories (LCL), with detailed pathogen characterisation at national reference laboratories. - A commercial Genetic Signatures assay was evaluated in a routine diagnostic setting using commercially-provided pathogen controls, reference isolates and clinical samples, enabling the inclusion of Aeromonas and ETEC PCR targets into the diagnostic panel. - Real-time referrals of PCR-reactive samples were made to UK Health Security Agency (UKHSA) regardless of bacterial culture results, and to Public Health Wales (PHW). - Norovirus PCR-reactive samples were referred to the Enteric Virus Unit at UKHSA for genotyping ahead of Norovirus becoming a notifiable infection on the 6 th of April 2025, adding valuable information on Norovirus genotypes circulating in the general population. - A Biobank has been created for residual faecal specimens, forming a rich resource for future studies. - A major challenge was the lack of a harmonised UK-wide digital referral and reporting system, resulting in an inflated manual reporting workload for staff at LCL.
- Open Access
- 9 October 2025
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 30 (40) , 2500757
Author’s response: Peanut butter confirmed as the source of a case of infant botulism in the United Kingdom, 2024
Eurosurveillance.org is the online home of Eurosurveillance, Europe's journal on infectious disease surveillance, epidemiology, prevention and control.
- 9 October 2025
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 30 (40) , 2500757
Open AccessAuthor’s response: Peanut butter confirmed as the source of a case of infant botulism in the United Kingdom, 2024
Eurosurveillance.org is the online home of Eurosurveillance, Europe's journal on infectious disease surveillance, epidemiology, prevention and control.
- Open Access
- 31 July 2025
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 30 (30) , 2500512
Peanut butter confirmed as the source in a case of infant botulism, United Kingdom, 2024
A 6-month-old infant was hospitalised with suspected infant botulism after being given peanut butter to reduce their risk of developing peanut allergy. Clostridium botulinum type A was detected in their faeces and the peanut butter by PCR and culture. Whole genome sequencing confirmed identical strains, identifying the peanut butter as the source of infection. The infant was treated with human-derived antitoxin Botulism Immune Globulin Intravenous (Human) (BIG-IV) and recovered well. This case highlights potential botulism risk with early peanut introduction.
- 31 July 2025
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 30 (30) , 2500512
Open AccessPeanut butter confirmed as the source in a case of infant botulism, United Kingdom, 2024
A 6-month-old infant was hospitalised with suspected infant botulism after being given peanut butter to reduce their risk of developing peanut allergy. Clostridium botulinum type A was detected in their faeces and the peanut butter by PCR and culture. Whole genome sequencing confirmed identical strains, identifying the peanut butter as the source of infection. The infant was treated with human-derived antitoxin Botulism Immune Globulin Intravenous (Human) (BIG-IV) and recovered well. This case highlights potential botulism risk with early peanut introduction.
- Open Access
- 7 July 2025
- Published by Microbiology Society in Microbial Genomics
- Vol. 11 (7) , 001445
Characterization of a Listeria monocytogenes plasmid with antibiotic and stress resistance genes
Listeriosis is a predominantly foodborne infection causing severe, invasive disease in the immunocompromised, with the causative agent being Listeria monocytogenes. While L. monocytogenes possesses innate resistance to several classes of antibiotics, acquired antibiotic resistance is low compared with other foodborne pathogens. Conversely, plasmids possessing stress tolerance mechanisms are common and contribute to their ability to persist in food production environments. However, very few have been identified, which also carry antibiotic resistance genes, particularly multidrug resistance regions. We scanned a UK collection of L. monocytogenes genomes and detected an isolate with the dfrD, lnuG and mphB genes, encoding predicted resistance to trimethoprim, lincosamides and macrolides, respectively. This isolate also possessed a Listeria repA family plasmid replication gene, as well as multiple chromosomal and plasmid-associated stress tolerance factors. Long-read sequencing confirmed the presence of a single 120,420 bp plasmid, which notably is a composite of a highly conserved Listeria plasmid backbone with a novel 35 kb resistance region. Comparative genomic analyses revealed that the plasmid-borne resistance region was likely acquired from other Gram-positive species over several events. The island containing the lnuG and mphB genes has links to porcine and bovine origins, while the dfrD gene is located on a Tn3-like transposon associated with multiple resistance genes, and both elements can move to the chromosome of L. monocytogenes strains from food and human disease. This work furthers the understanding of plasmid-mediated antibiotic resistance as well as the wider circulation of mobile genetic elements among L. monocytogenes and other bacterial species within the food chain.
- 7 July 2025
- Published by Microbiology Society in Microbial Genomics
- Vol. 11 (7) , 001445
Open AccessCharacterization of a Listeria monocytogenes plasmid with antibiotic and stress resistance genes
Listeriosis is a predominantly foodborne infection causing severe, invasive disease in the immunocompromised, with the causative agent being Listeria monocytogenes. While L. monocytogenes possesses innate resistance to several classes of antibiotics, acquired antibiotic resistance is low compared with other foodborne pathogens. Conversely, plasmids possessing stress tolerance mechanisms are common and contribute to their ability to persist in food production environments. However, very few have been identified, which also carry antibiotic resistance genes, particularly multidrug resistance regions. We scanned a UK collection of L. monocytogenes genomes and detected an isolate with the dfrD, lnuG and mphB genes, encoding predicted resistance to trimethoprim, lincosamides and macrolides, respectively. This isolate also possessed a Listeria repA family plasmid replication gene, as well as multiple chromosomal and plasmid-associated stress tolerance factors. Long-read sequencing confirmed the presence of a single 120,420 bp plasmid, which notably is a composite of a highly conserved Listeria plasmid backbone with a novel 35 kb resistance region. Comparative genomic analyses revealed that the plasmid-borne resistance region was likely acquired from other Gram-positive species over several events. The island containing the lnuG and mphB genes has links to porcine and bovine origins, while the dfrD gene is located on a Tn3-like transposon associated with multiple resistance genes, and both elements can move to the chromosome of L. monocytogenes strains from food and human disease. This work furthers the understanding of plasmid-mediated antibiotic resistance as well as the wider circulation of mobile genetic elements among L. monocytogenes and other bacterial species within the food chain.
- Open Access
- 10 January 2025
- Published by Microbiology Society in Journal of Medical Microbiology
- Vol. 74 (1) , 001947
Epidemiology of Shiga toxin-producing Escherichia coli other than serotype O157:H7 in England, 2016–2023
Introduction. Shiga toxin-producing Escherichia coli (STEC) infections are of public health concern as STEC can cause large national foodborne outbreaks of severe gastrointestinal disease, particularly in the young and elderly. In recent years, the implementation of PCR by diagnostic microbiology laboratories has improved the detection of STEC, and there has been an increase in notifications of cases of non-O157 STEC. However, the extent this increase in caseload can be attributed to the improved detection by PCR, or a true increase in non-O157 STEC infections, is unknown. Gap Statement. Epidemiological and microbiological data and analyses describing the trends in non-O157 STEC in England since the implementation of PCR are limited. Aim. Demographic, microbiological and clinical characteristics of non-O157 STEC from 8 years (2016–2023) of laboratory surveillance data were analysed to understand the recent trends in non-O157 serotypes and the incidence of disease in England. Methodology. All human isolates of STEC non-O157 detected between 2016 and 2023 were extracted from the laboratory surveillance system. Microbiological data were analysed and linked to clinical outcomes. Results. There was an almost 10-fold increase in diagnoses of non-O157 STEC from 2016 (n=297) to 2023 (n=2341). A total of 9378 isolates of non-O157 STEC were detected, comprising 338 different serotypes, and were linked to 9311 individuals. A higher proportion of non-O157 STEC cases were female (56%) and aged between 20 and 39 years (27%). The most common non-O157 serotypes were O26:H11 (16%), O146:H21 (12%), O91:H14 (11%), O128:H2 (6%), O145:H28 (5%) and O103:H2 (4%). STEC O26:H11 was more frequently reported in under 5s than any other age group (38%), whereas the other common serotypes were more frequently isolated from adults. Stx2a, which has been associated with greater disease severity, was detected in 18% of cases. Where clinical details were available, 27% of non-O157 cases were admitted to the hospital and 6% developed HUS. Cases of STEC O145:H28 reported a higher rate of hospitalisation than other non-O157 STEC cases. The serotypes most likely to be associated with progression to HUS were O26:H11 (9%) and O145:H28 (7%). STEC harbouring stx2f (19%), stx2a (11%) and stx2d (11%) were most frequently isolated from cases with HUS. Conclusion. The implementation of widespread PCR testing in England has facilitated better surveillance of STEC non-O157, with respect to establishing the true incidence and burden of disease of non-O157 STEC and monitoring the emergence of highly virulent strains.
- 10 January 2025
- Published by Microbiology Society in Journal of Medical Microbiology
- Vol. 74 (1) , 001947
Open AccessEpidemiology of Shiga toxin-producing Escherichia coli other than serotype O157:H7 in England, 2016–2023
Introduction. Shiga toxin-producing Escherichia coli (STEC) infections are of public health concern as STEC can cause large national foodborne outbreaks of severe gastrointestinal disease, particularly in the young and elderly. In recent years, the implementation of PCR by diagnostic microbiology laboratories has improved the detection of STEC, and there has been an increase in notifications of cases of non-O157 STEC. However, the extent this increase in caseload can be attributed to the improved detection by PCR, or a true increase in non-O157 STEC infections, is unknown. Gap Statement. Epidemiological and microbiological data and analyses describing the trends in non-O157 STEC in England since the implementation of PCR are limited. Aim. Demographic, microbiological and clinical characteristics of non-O157 STEC from 8 years (2016–2023) of laboratory surveillance data were analysed to understand the recent trends in non-O157 serotypes and the incidence of disease in England. Methodology. All human isolates of STEC non-O157 detected between 2016 and 2023 were extracted from the laboratory surveillance system. Microbiological data were analysed and linked to clinical outcomes. Results. There was an almost 10-fold increase in diagnoses of non-O157 STEC from 2016 (n=297) to 2023 (n=2341). A total of 9378 isolates of non-O157 STEC were detected, comprising 338 different serotypes, and were linked to 9311 individuals. A higher proportion of non-O157 STEC cases were female (56%) and aged between 20 and 39 years (27%). The most common non-O157 serotypes were O26:H11 (16%), O146:H21 (12%), O91:H14 (11%), O128:H2 (6%), O145:H28 (5%) and O103:H2 (4%). STEC O26:H11 was more frequently reported in under 5s than any other age group (38%), whereas the other common serotypes were more frequently isolated from adults. Stx2a, which has been associated with greater disease severity, was detected in 18% of cases. Where clinical details were available, 27% of non-O157 cases were admitted to the hospital and 6% developed HUS. Cases of STEC O145:H28 reported a higher rate of hospitalisation than other non-O157 STEC cases. The serotypes most likely to be associated with progression to HUS were O26:H11 (9%) and O145:H28 (7%). STEC harbouring stx2f (19%), stx2a (11%) and stx2d (11%) were most frequently isolated from cases with HUS. Conclusion. The implementation of widespread PCR testing in England has facilitated better surveillance of STEC non-O157, with respect to establishing the true incidence and burden of disease of non-O157 STEC and monitoring the emergence of highly virulent strains.
- Open Access
- 7 October 2024
- Published by BMJ in Frontline Gastroenterology
- Vol. 16 (1) , 37-50
Recent advances in the diagnosis and management of amoebiasis
With increasing international travel and migration, tropical and infectious diseases once largely confined to specialist institutes now present more widely. Amoebiasis is a potentially dangerous example since it may closely mimic the presentation of inflammatory bowel disease. Misdiagnosis and treatment with immunosuppressants can result in fulminant amoebiasis and death. This review considers the epidemiology, pathogenesis, clinical features, diagnosis and treatment of intestinal and extraintestinal amoebiasis. It is written primarily for gastroenterologists, surgeons and acute physicians.
- 7 October 2024
- Published by BMJ in Frontline Gastroenterology
- Vol. 16 (1) , 37-50
Open AccessRecent advances in the diagnosis and management of amoebiasis
With increasing international travel and migration, tropical and infectious diseases once largely confined to specialist institutes now present more widely. Amoebiasis is a potentially dangerous example since it may closely mimic the presentation of inflammatory bowel disease. Misdiagnosis and treatment with immunosuppressants can result in fulminant amoebiasis and death. This review considers the epidemiology, pathogenesis, clinical features, diagnosis and treatment of intestinal and extraintestinal amoebiasis. It is written primarily for gastroenterologists, surgeons and acute physicians.
- Open Access
- 13 April 2023
- Published by Elsevier in Journal of Infection
- Vol. 86 (6) , 552-562
The epidemiology of Shiga toxin-producing Escherichia coli O26:H11 (clonal complex 29) in England, 2014–2021
- 13 April 2023
- Published by Elsevier in Journal of Infection
- Vol. 86 (6) , 552-562
Open AccessThe epidemiology of Shiga toxin-producing Escherichia coli O26:H11 (clonal complex 29) in England, 2014–2021